A Phase I/ Randomized Phase II Study of Gemcitabine Plus Erlotinib Plus MK-0646; Gemcitabine Plus MK-0646 and Gemcitabine Plus Erlotinib for Patients With Advanced Pancreatic Cancer (IISP33337).
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 25 Nov 2016
At a glance
- Drugs Dalotuzumab (Primary) ; Erlotinib; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 22 Nov 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 17 Nov 2015 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017, according to ClinicalTrials.gov record.
- 03 Nov 2014 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016, according to ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History